用于检测和定量丝氨酸/苏氨酸激酶 polo-like kinase 1 的生物正交探针
Bioorthogonal probes for polo-like kinase 1 imaging and quantification.
机构信息
Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
出版信息
Angew Chem Int Ed Engl. 2011 Sep 26;50(40):9378-81. doi: 10.1002/anie.201103273. Epub 2011 Aug 24.
Abstract
[Image: see text] A nuclear protein target, polo-like kinase 1 (PLK1) was imaged using a biocompatible bioorthogonal ligation between a specific drug and a fluorescent dye in live cells. Colocalization of the dye and the protein target was confirmed by antibody staining and by expressing a GFP construct of PLK1. The two-step PLK1 imaging procedure was used to quantify PLK1 expression levels in cancer cell lines of various tissue origins.
摘要
[图片：见正文]利用活细胞中特定药物与荧光染料之间的生物正交连接，对核蛋白靶标丝氨酸/苏氨酸激酶 PLK1 进行了成像。通过抗体染色和表达 GFP 构建体的 PLK1 证实了染料和蛋白质靶标的共定位。两步法 PLK1 成像程序用于定量各种组织来源的癌细胞系中的 PLK1 表达水平。
相似文献
1
Bioorthogonal probes for polo-like kinase 1 imaging and quantification.用于检测和定量丝氨酸/苏氨酸激酶 polo-like kinase 1 的生物正交探针
Angew Chem Int Ed Engl. 2011 Sep 26;50(40):9378-81. doi: 10.1002/anie.201103273. Epub 2011 Aug 24.
2
Enabling and disabling polo-like kinase 1 inhibition through chemical genetics.通过化学生物学遗传学来实现和禁用 polo 样激酶 1 的抑制作用。
ACS Chem Biol. 2012 Jun 15;7(6):978-81. doi: 10.1021/cb200551p. Epub 2012 Mar 20.
3
Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy.利用激酶抑制剂开发用于通过荧光显微镜对激酶进行成像的小分子工具。
Mol Biosyst. 2012 Oct;8(10):2523-6. doi: 10.1039/c2mb25099c.
4
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.BI6727，一种有前景的 Polo 样激酶 1 抑制剂，对 Burkitt 淋巴瘤细胞有效。
J Int Med Res. 2020 May;48(5):300060520926093. doi: 10.1177/0300060520926093.
5
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.抑制 Polo 样激酶 1 导致骨肉瘤细胞在体外和体内生长受到抑制。
Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.
6
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.BI 6727，一种具有改善药代动力学特征和广泛抗肿瘤活性的类Polo样激酶抑制剂。
Clin Cancer Res. 2009 May 1;15(9):3094-102. doi: 10.1158/1078-0432.CCR-08-2445. Epub 2009 Apr 21.
7
Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.Polo样激酶1作为一种有前景的肝细胞癌诊断生物标志物和潜在治疗靶点。
Tumour Biol. 2020 Apr;42(4):1010428320914475. doi: 10.1177/1010428320914475.
8
Using transcriptome sequencing to identify mechanisms of drug action and resistance.利用转录组测序技术鉴定药物作用和耐药机制。
Nat Chem Biol. 2012 Feb 12;8(3):235-7. doi: 10.1038/nchembio.779.
9
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.药物抑制polo样激酶1在视网膜母细胞瘤细胞系中发挥广泛的抗肿瘤活性。
Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.
10
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.作为一种新型的肿瘤肥大细胞靶点的 Polo 样激酶-1：小干扰 RNA 和 Polo 样激酶-1 靶向药物 BI 2536 的生长抑制作用的证明。
Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.
引用本文的文献
1
Titanocenes functionalization with high chemical diversity via titanium protecting groups.通过钛保护基团实现具有高化学多样性的二茂钛官能化。
Commun Chem. 2025 Jul 30;8(1):221. doi: 10.1038/s42004-025-01624-w.
2
Spatio-temporal control of mitosis using light via a Plk1 inhibitor caged for activity and cellular permeability.通过一种经光笼化以实现活性和细胞通透性的Plk1抑制剂对有丝分裂进行时空控制。
Nat Commun. 2025 Feb 19;16(1):1599. doi: 10.1038/s41467-025-56746-5.
3
Chemical Probe for Imaging of Polo-like Kinase 4 and Centrioles.用于成像Polo样激酶4和中心粒的化学探针。
JACS Au. 2023 Aug 4;3(8):2247-2256. doi: 10.1021/jacsau.3c00271. eCollection 2023 Aug 28.
4
Polymer-Supported Synthesis of Various Pteridinones and Pyrimidodiazepinones.聚合物支持的各种蝶啶酮和嘧啶二氮杂卓的合成。
Molecules. 2021 Mar 14;26(6):1603. doi: 10.3390/molecules26061603.
5
Asymmetric Synthesis of N-Substituted α-Amino Esters from α-Ketoesters via Imine Reductase-Catalyzed Reductive Amination.通过亚胺还原酶催化的还原胺化反应，从α-酮酯不对称合成 N-取代的α-氨基酯。
Angew Chem Int Ed Engl. 2021 Apr 12;60(16):8717-8721. doi: 10.1002/anie.202016589. Epub 2021 Mar 9.
6
A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors.一种用于评估polo样激酶1 ATP竞争性抑制剂的新型荧光恢复测定法。
Anal Methods. 2020 Sep 28;12(36):4418-4421. doi: 10.1039/d0ay01223h. Epub 2020 Sep 3.
7
Biomedical applications of copper-free click chemistry: , , and .无铜点击化学的生物医学应用： ， ，以及 。
Chem Sci. 2019 Aug 16;10(34):7835-7851. doi: 10.1039/c9sc03368h. eCollection 2019 Sep 14.
8
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.设计针对间变性淋巴瘤激酶（ALK）和溴结构域蛋白 4（BRD4）的双重抑制剂：调节激酶选择性。
J Med Chem. 2019 Mar 14;62(5):2618-2637. doi: 10.1021/acs.jmedchem.8b01947. Epub 2019 Feb 21.
9
The discovery of pyridinium 1,2,4-triazines with enhanced performance in bioconjugation reactions.在生物共轭反应中具有增强性能的吡啶鎓1,2,4 - 三嗪的发现。
Chem Sci. 2017 May 1;8(5):3593-3598. doi: 10.1039/c6sc05442k. Epub 2017 Mar 1.
10
Tetrazine ligation for chemical proteomics.用于化学蛋白质组学的四嗪连接反应
Proteome Sci. 2017 Jun 26;15:15. doi: 10.1186/s12953-017-0121-5. eCollection 2016.
本文引用的文献
1
Adaptive informatics for multifactorial and high-content biological data.多因素和高内涵生物学数据的自适应信息学。
Nat Methods. 2011 Jun;8(6):487-93. doi: 10.1038/nmeth.1600. Epub 2011 Apr 24.
2
Bioorthogonal turn-on probes for imaging small molecules inside living cells.用于在活细胞内成像小分子的生物正交型开启探针。
Angew Chem Int Ed Engl. 2010 Apr 6;49(16):2869-72. doi: 10.1002/anie.200906120. Epub 2010 Mar 19.
3
Selectivity-determining residues in Plk1.Polo样激酶1（Plk1）中决定选择性的残基
Chem Biol Drug Des. 2007 Dec;70(6):540-6. doi: 10.1111/j.1747-0285.2007.00594.x. Epub 2007 Nov 13.
4
Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate.蛋白质组学筛选确定了Polo盒结构域相互作用组并将Rock2鉴定为Plk1底物。
EMBO J. 2007 May 2;26(9):2262-73. doi: 10.1038/sj.emboj.7601683. Epub 2007 Apr 19.
5
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.BI 2536，一种强效且选择性的polo样激酶1抑制剂，可在体内抑制肿瘤生长。
Curr Biol. 2007 Feb 20;17(4):316-22. doi: 10.1016/j.cub.2006.12.037. Epub 2007 Feb 8.
6
Polo-like kinases: a team in control of the division.Polo样激酶：控制细胞分裂的一组蛋白
Cell Cycle. 2006 Apr;5(8):853-64. doi: 10.4161/cc.5.8.2692. Epub 2006 Apr 17.
7
Targeting polo-like kinase 1 for cancer therapy.靶向Polo样激酶1用于癌症治疗。
Nat Rev Cancer. 2006 Apr;6(4):321-30. doi: 10.1038/nrc1841.
8
Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting.不同的Plk1功能对Polo-Box结构域介导的靶向作用表现出不同的依赖性。
Mol Biol Cell. 2006 Jan;17(1):448-59. doi: 10.1091/mbc.e05-08-0801. Epub 2005 Nov 2.
9
Polo-like kinases and oncogenesis.Polo样激酶与肿瘤发生
Oncogene. 2005 Jan 10;24(2):267-76. doi: 10.1038/sj.onc.1208273.
10
M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP.M期激酶通过SCFβ-TrCP诱导体细胞型Wee1发生磷酸化依赖性泛素化。
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4419-24. doi: 10.1073/pnas.0307700101. Epub 2004 Mar 22.
Zotero 插件